SLC35F2 and cancer: Recent studies have discovered that USP32 contributes to drug resistance in cancer: In several kinds of cancer cells, USP32 can confer cell resistance to a small molecule inhibitor YM155 (Sepantronium bromide) through promoting the degradation of SLC35F2, a solute-carrier protein that is essential for the uptake of YM155 [44].